Catalyst
Slingshot members are tracking this event:
Feedback on aplidin (plitidepsin) in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma from the EMA expected in the second half of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
PHM.MC | Community voting in process |
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 09, 2017
Occurred Source:
https://www.pharmamar.com/wp-content/uploads/2017/08/PR_Quadruple-combination_Aplidin.pdf
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Multiple Myeloma, Aplidin